Scientist/Senior Scientist, Preclinical Development and Translational Science at Abata Therapeutics

New York, New York, United States

Apply Now

Not SpecifiedCompensation

Mid-level (3 to 4 years), Senior (5 to 8 years)Experience Level

Full TimeJob Type

UnknownVisa

Biotechnology, OncologyIndustries

Requirements

MS in related field, PhD a plus but not required
2+ years of industry experience in preclinical development and clinical oncology biomarker
5+ years of hands-on lab experience with a range of relevant research techniques including cell-based assays, molecular biology, and histology. In vivo mouse experience is preferred
Knowledge of antibody drug conjugates (ADC) biology and broad experience with in vitro and in vivo ADC testing
Experience in the development and validation of biomarker assays suitable for clinical samples
Track record of successfully managing external projects with CRO’s from scoping to final data delivery
Understanding of the drug development process from target identification to marketing authorization
Basic understanding of regulatory aspects of medical diagnostics
Excellent communication, organizational, and problem-solving skills

Responsibilities

In collaboration with other members of the Translational Science and the Discovery Science team, design and execute experimental plans to answer important translational questions to inform clinical development plans
Coordinate and oversee studies at contract research organizations
Execution and development of existing and/or new assays and assay strategies related to biomarker application and validation
Coordinate activities and timelines with Development teams to ensure seamless execution of biomarker capabilities to support clinical trials
Work closely with relevant team members to analyze, interpret and communicate translational results
Assist in preparation of relevant documents and reports including meeting presentations, biomarker reports, and regulatory submission documents

Skills

preclinical development

translational science

biomarkers

laboratory skills

oncology

KIF18A inhibitors

Abata Therapeutics

Develops therapies for autoimmune diseases

About Abata Therapeutics

Abata Therapeutics develops therapies for autoimmune diseases, focusing on type 1 diabetes. Their main product, ABA 201, is a Treg cell therapy aimed at patients with some remaining beta cell function. This therapy works by utilizing regulatory T cells to improve patient outcomes. Unlike many competitors, Abata targets a specific niche within the autoimmune disease market and collaborates with partners like ElevateBio for process development and manufacturing. The company's goal is to transform treatment options for autoimmune diseases through advanced research and development.

Cambridge, MassachusettsHeadquarters

2021Year Founded

$184.8MTotal Funding

EARLY_VCCompany Stage

BiotechnologyIndustries

11-50Employees

Risks

Intensifying competition from companies like Sangamo Therapeutics may impact Abata's market share.

Stringent FDA scrutiny on manufacturing could delay Abata's clinical trials.

Rising clinical trial costs pose financial risks to Abata's pipeline progression.

Differentiation

Abata focuses on Treg cell therapies for autoimmune diseases like MS and diabetes.

Their lead product, ABA 201, targets type 1 diabetes with remaining beta cell function.

Abata's strategic partnership with ElevateBio enhances their manufacturing capabilities.

Upsides

Recent investment from Bristol Myers Squibb boosts Abata's Treg therapy pipeline development.

FDA's accelerated approval pathways may expedite Abata's clinical trials.

Growing autoimmune disease prevalence increases demand for Abata's innovative treatments.

Land your dream remote job 3x faster with AI

Try Jobo Free